Ikarian Capital’s Vaxcyte PCVX Stock Holding History

Ikarian Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.6M	Sell	388,682 -40,000	-9%	-$2.17M	2.43%	11
2026 Q1	$24.9M	Buy	428,682 +50,000	+13%	+$2.71M	2.02%	12
2025 Q4	$17.5M	Buy	378,682 +67,000	+21%	+$3M	1.36%	17
2025 Q3	$11.2M	Buy	311,682 +6,682	+2%	+$221K	1.13%	22
2025 Q2	$9.92M	Buy	305,000 +105,000	+53%	+$3.44M	1.9%	18
2025 Q1	$7.55M	Buy	+200,000	New	+$16M	0.93%	20
2023 Q4	–	Sell	-142,417	Closed	-$7.26M	–	164
2023 Q3	$7.26M	Buy	142,417 +2,417	+2%	+$119K	0.87%	32
2023 Q2	$6.99M	Sell	140,000 -85,000	-38%	-$4.03M	1.11%	28
2023 Q1	$8.43M	Sell	225,000 -25,000	-10%	-$1.06M	1.91%	15
2022 Q4	$12M	Buy	+250,000	New	+$9.81M	2.89%	5
2022 Q3	–	Sell	-225,991	Closed	-$4.92M	–	149
2022 Q2	$4.92M	Sell	225,991 -90,000	-28%	-$2.08M	0.9%	37
2022 Q1	$7.63M	Buy	315,991 +20,880	+7%	+$456K	1%	27
2021 Q4	$7.02M	Hold	295,111	–	–	1.05%	26
2021 Q3	$7.49M	Sell	295,111 -152,999	-34%	-$3.71M	0.53%	49
2021 Q2	$10.1M	Sell	448,110 -53,000	-11%	-$1.09M	0.82%	34
2021 Q1	$9.9M	Buy	501,110 +225,000	+81%	+$5.66M	0.33%	70
2020 Q4	$7.34M	Buy	276,110 +260,000	+1,614%	+$9.67M	0.32%	72
2020 Q3	$796K	Sell	16,110 -123,703	-88%	-$4.93M	0.06%	132
2020 Q2	$4.42M	Buy	+139,813	New	+$4.5M	0.35%	72

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ikarian Capital's PCVX Position: Q2 2026 in Review

Ikarian Capital reduced its Vaxcyte (PCVX) stake by 9.3% in Q2 2026, selling an estimated $2.17M and leaving 388,682 shares worth $22.6M. The position accounts for 2.43% of the portfolio, ranked #11.

Ikarian Capital first reported a position in PCVX in Q2 2020 and has held it in 19 quarters since. The position peaked at $24.9M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Ikarian Capital held 388,682 shares of Vaxcyte worth $22.6M as of Q2 2026.
Ikarian Capital sold 40,000 Vaxcyte shares in Q2 2026, an estimated $2.17M.
Vaxcyte made up 2.43% of Ikarian Capital's portfolio in Q2 2026, its #11 holding.
Ikarian Capital first reported a position in Vaxcyte in Q2 2020 and has held it in 19 quarters since.
Ikarian Capital's Vaxcyte position peaked at $24.9M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.